- Variceal hemorrhage: hematemesis, melena, hemodynamic instability
- Spontaneous bacterial peritonitis (SBP): fever, abdominal pain, ascites – diagnostic paracentesis with PMN >250 cells/μL
- Hepatorenal syndrome: rapid renal deterioration in decompensated cirrhosis
Cirrhosis and Portal Hypertension
Must-Not-Miss / Red Flags
Definition & Core Concept
Cirrhosis is the end‑stage of chronic liver disease, characterized by diffuse fibrosis and nodular regeneration, leading to portal hypertension, synthetic dysfunction, and risk of hepatocellular carcinoma.
Epidemiology & Risk Factors
- Leading cause of liver‑related death worldwide
- Common causes: hepatitis C, alcohol‑related liver disease, non‑alcoholic fatty liver disease (NAFLD), hepatitis B
- Compensated cirrhosis has median survival >12 years; decompensated (ascites, variceal bleed, encephalopathy) median survival ~2 years
Pathophysiology (Rule of 3)
- Chronic hepatocyte injury → inflammation and stellate cell activation → fibrosis
- Nodular regeneration distorts hepatic architecture → increased intrahepatic resistance → portal hypertension
- Portal hypertension → portosystemic shunting, splanchnic vasodilation → ascites, varices, encephalopathy
Clinical Presentation
- Compensated: may be asymptomatic or have nonspecific fatigue, anorexia
- Decompensated: ascites (abdominal distension), jaundice, spider angiomas, palmar erythema, caput medusae, hepatic encephalopathy (confusion, asterixis), variceal bleeding
Diagnostic Workup
Labs: AST/ALT ratio >1, thrombocytopenia (portal hypertension), prolonged PT/INR, low albumin. Liver ultrasound with Doppler: nodular surface, portal vein flow. FibroScan: measures liver stiffness. Endoscopy: screen for varices. Paracentesis: if ascites to rule out SBP.
Management Protocol
- Ascites: Sodium restriction <2g/day, diuretics (Spironolactone 100‑400 mg + Furosemide 40‑160 mg). Large volume paracentesis for refractory ascites
- Varices: Non‑selective beta‑blockers (Propranolol, Carvedilol) for primary prophylaxis; band ligation for secondary prophylaxis. Octreotide + endoscopic therapy for acute bleed
- Encephalopathy: Lactulose 30 mL BID titrated to 2‑3 soft stools/day; Rifaximin 550 mg BID
- HCC surveillance: abdominal ultrasound ± AFP every 6 months
- Liver transplantation evaluation if MELD ≥15 or decompensated
Complications & Prognosis
- Variceal hemorrhage (mortality 15‑20% per episode)
- Hepatorenal syndrome (Type 1: rapid; Type 2: slow)
- Spontaneous bacterial peritonitis
- Hepatocellular carcinoma
ICU Criteria
ICU admission if: acute variceal hemorrhage, hepatorenal syndrome, septic shock from SBP, or hepatic encephalopathy with airway compromise.
Clinical Vignette
Pearls & Pitfalls
- Always perform diagnostic paracentesis in any cirrhotic patient with ascites admitted to the hospital – SBP is common and often asymptomatic.
- Use lactulose for hepatic encephalopathy, but avoid oversedation – benzodiazepines worsen encephalopathy.
Discharge & Follow-Up
Monthly weight and ascites monitoring. Repeat variceal screening per guidelines. Adherence to lactulose and diuretics. Alcohol abstinence. Refer to hepatologist and transplant center.
Literature & Guidelines
AASLD 2024 Practice Guidance on Cirrhosis. PMID: 38723100.